News & Views | Published:

Fabry disease

A pharmacological chaperone on the horizon

Nature Reviews Nephrology volume 12, pages 653654 (2016) | Download Citation

For more than a decade, enzyme replacement therapy represented the only treatment option for patients with Fabry disease. New findings suggest that a pharmacological chaperone can induce renal substrate clearance, decrease left ventricular mass and improve gastrointestinal symptoms in patients with specific mutations in GLA.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Narrative review: Fabry disease. Ann. Intern. Med. 146, 425–433 (2007).

  2. 2.

    et al. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol. Genet. Metab. 95, 114–115 (2008).

  3. 3.

    Fabry disease: is there a role for enzyme replacement therapy? J. Intern. Med. 274, 329–330 (2013).

  4. 4.

    Migalastat: first global approval. Drugs 76, 1147–1152 (2016).

  5. 5.

    et al. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J. Rare Dis. 7, 91 (2012).

  6. 6.

    et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 375, 545–555 (2016).

  7. 7.

    et al. Long-term efficacy and safety of migalastat compared to enzyme replacement therapy in Fabry disease: phase 3 study results. Mol. Genet. Metab. 114, S57 (2015).

  8. 8.

    et al. Oral migalastat HCl leads to greater systemic exposure and tissue levels of active α-galactosidase A in Fabry patients when co-administered with infused agalsidase. PLoS ONE 10, e0134341 (2015).

  9. 9.

    et al. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J. Am. Soc. Nephrol. 27, 256–264 (2016).

  10. 10.

    , & Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem. Commun. 52, 5497–5515 (2016).

Download references

Author information

Affiliations

  1. Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Währinger Gürtel 18–20, Vienna 1090, Austria.

    • Martina Gaggl
    •  & Gere Sunder-Plassmann

Authors

  1. Search for Martina Gaggl in:

  2. Search for Gere Sunder-Plassmann in:

Competing interests

M.G. has received a travel grant from Shire HGT. G.S.-P. has received funding from Amicus, Sanofi-Genzyme, and Shire HGT. G.S.-P. and M.G. are investigators of the ATTRACT trial.

Corresponding authors

Correspondence to Martina Gaggl or Gere Sunder-Plassmann.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrneph.2016.138

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing